RecruitingPhase 1NCT06414434
BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma
Studying Myxoid/round cell liposarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Michael Wagner, MD
- Principal Investigator
- Michael Wagner, MDDana-Farber Cancer Institute
- Intervention
- BTX-A51(drug)
- Enrollment
- 24 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2027
Study locations (2)
- Brigham and Women's Hospital, Boston, Massachusetts, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Collaborators
Edgewood Oncology Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06414434 on ClinicalTrials.govOther trials for Myxoid/round cell liposarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06644755First-in-Human Trial of DS-2243a in Participants With Advanced Solid TumorsDaiichi Sankyo
- RECRUITINGPHASE1NCT06083883Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1M.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE1NCT05492682START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of CancerValo Therapeutics Oy
- ACTIVE NOT RECRUITINGPHASE2NCT04044768Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell LiposarcomaUSWM CT, LLC